Thanks for getting that info Cabel.  Yes, a primary publication is a good reason not to present the data (i.e. it is considered a prior publication of the same data which the authors must state has not happened).  RVX had previously mentioned publication embargoes but then suggested that the CTAD embargo was the last one.  I hope this means that they expect the publication to come out before CTAD but that is the optimistic interpretation.  Possible that DM did not realize how hungry for the 'data, data, data' the investors would be (i.e. thought we wouldn't notice that the eGFR data wasn't presented for the CKD subgroup in the AHA and followup presentations).  Let's get that kimono lifted.

Jupe